Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone

• Published in: Transplant international Vol. 14; no. 2; p. 99
• Main Authors: ter Meulen, C G, Gregoor, P J, Weimar, W, Hilbrands, L B
• Format: Journal Article
• Language: English
• Published: England 2001
• Subjects: Adolescent; Adult; Aged; Anti-Inflammatory Agents - administration & dosage; Cyclosporine - administration & dosage; Female; Graft Rejection - prevention & control; Humans; Immunosuppressive Agents - administration & dosage; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid - administration & dosage; Mycophenolic Acid - analogs & derivatives; Prednisone - administration & dosage; Retrospective Studies; Treatment Outcome
• ISSN: 0934-0874
• DOI: 10.1007/s001470050854

In a retrospective study we investigated the risk of acute rejection after the withdrawal of mycophenolate mofetil (MMF) in 39 adult patients treated with cyclosporine (CyA), prednisone, and MMF for at least 6 months following renal transplantation. After reaching a stable renal graft function, MMF was withdrawn and CyA and prednisone were continued. Preceding the withdrawal of MMF, four patients experienced an acute rejection. During a median follow-up of 38 months after discontinuing MMF, no acute rejection occurred. The mean serum creatinine level did not change during the first 6 months after withdrawal of MMF. We conclude that elective withdrawal of MMF in stable renal transplant recipients at 6 months after transplantation bears no important risk of an occurrence of acute rejection.